Navigation Links
Drugs used to tackle hospital-acquired infections can increase post-op complications
Date:10/31/2011

The introduction of new antibiotic regimes to tackle hospital-acquired infections, such as C. difficile, must take into account the possibility of increased infections following specific surgical procedures. That is the key finding of a study published in the November issue of the urology journal BJUI.

UK researchers from Addenbrooke's Hospital, Cambridge discovered that patients undergoing a standard surgical procedure to diagnose prostate cancer developed more than five times as many infective complications when a new standard antibiotic regime was introduced.

These included a number of cases of sepsis and one case of septic shock, which they describe as a highly significant finding.

"The change, based on national guidance, reflected concerns that C. difficile rates were being driven by the widespread use of broad-spectrum antibiotics such as ciprofloxacin" explains departmental lead and senior author Professor David Neal. "The new regime was introduced on the proviso that both the hospital-acquired infection rates and post-operative infection rates would be closely monitored.

"Given that there were no cases of C. difficile recorded in our study, but post-operative infection rates increased significantly, the decision was taken to revert back to the original regime."

Records for 709 consecutive patients who received transrectal ultrasound-guided prostate biopsy surgery (TRUSP Bx) over a period of 20 months were studied. These showed that:

  • Only 2.4 per cent of the 454 patients treated with the original regime of prophylaxis with ciprofloxacin developed an infective complication within four weeks of surgery and four (0.9 per cent) were admitted for complications.

  • 12.9 per cent of the patients treated with the new regime of prophylaxis with co-amoxiclav and gentamicin developed an infective complication within four weeks of surgery. Twelve patients (4.7 per cent) were admitted for complications.

  • Seven of the 12 patients readmitted after being treated with the new regime were admitted with sepsis - in which the bloodstream is overwhelmed by bacteria - and a further patient had septic shock, which required inotropic support for 24 hours. None of the patients on the original regime had these very serious complications.

  • None of the patients developed C. difficile within one month of receiving antibiotics.

  • Reintroducing the original regime led to a fall in infective complications.

"Even though TRUSP Bx is a common urological procedure there are currently no national guidelines regarding antibiotic prophylaxis and local protocols vary widely across the UK" says Professor Neal. "However, the importance of using prophylaxis for a biopsy, to reduce the occurrence of infective complications following surgery, has been well documented.

"This is the first study to compare the use of co-amoxiclav and gentamicin with the use of ciprofloxacin for TRUSP Bx. Patients given the original ciprofloxacin regime experienced significantly fewer infective complications than those on the new regime and this audit study supports the use of locally determined prophylactic regimes for this procedure."

The authors stress that antibiotic prophylaxis needs to reflect the local situation, both in terms of tissue penetration, the organisms encountered and their susceptibilities and the local C. difficile rates. They add that any changes also need to be subject to frequent review.

"Any alteration to existing departmental antibiotic policies should be linked to strong clinical evidence, because such changes may potentially result in significant ill health and potential harm, as well as the financial burden of treating new complications" concludes Professor Neal.


'/>"/>

Contact: Annette Whibley
annette.wizard@gmail.com
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Some People With Alzheimers Take Conflicting Drugs
2. Study indicates nanoparticles could help pain-relieving osteoarthritis drugs last longer
3. Many Alzheimers patients get drugs with opposing effects
4. Some Asthma Drugs Raise Risk of Complications, Especially in Kids: Study
5. New anti-inflammatory drugs might help avoid side effects of steroids
6. Double duty for blood pressure drugs: how they could revolutionize how we treat valve disease
7. Are acid-suppressing drugs prescribed too often in infants?
8. Hypertension, Not Blood Pressure Drugs, Linked to Birth Defects
9. Antiviral drugs may slow Alzheimers progression
10. Tests to catch the makers of dangerous legal high designer drugs
11. $8.4 million grant supports health information exchange and research on Alzheimers drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: